Edwards Lifesciences (EW)

• Market cap: $41.3B
• 1 day: -1.04%
• 5 days: 1.74%
• 1 month: 4.15%
• 3 months: 3.10%
• 6 months: 10.00%
• Year to date: 4.00%
• 1 year: -10.84%
• 5 years: 4.12%
• 10 years: 257.60%
• Sector: Healthcare
• Industry: Medical Devices

About: Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Employees: 15,800

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

122% more call options, than puts

Call options by funds: $586M | Put options by funds: $264M

67% more funds holding in top 10

Funds holding in top 10: 6 [Q3] → 10 (+4) [Q4]

30% more first-time investments, than exits

New positions opened: 184 | Existing positions closed: 141

19% more capital invested

Capital invested by funds: $31.4B [Q3] → $37.5B (+$6.11B) [Q4]

6.28% more ownership

Funds ownership: 78.78% [Q3] → 85.06% (+6.28%) [Q4]

2% more funds holding

Funds holding: 1,180 [Q3] → 1,204 (+24) [Q4]

30% less repeat investments, than reductions

Existing positions increased: 347 | Existing positions reduced: 496

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $73 3% downside
• Avg. target: $79 4% upside
• High target: $90 19% upside

8 analyst ratings

• positive: 3 38%
• neutral: 5 63%
• negative: 0 0%

Canaccord Genuity William Plovanic 46% 1-year accuracy 22 / 48 met price target	1% downside $75	Hold Maintained	25 Apr 2025
Baird David Rescott 59% 1-year accuracy 10 / 17 met price target	1% downside $75	Neutral Maintained	24 Apr 2025
Piper Sandler Adam Maeder 54% 1-year accuracy 7 / 13 met price target	6% upside $80	Overweight Upgraded	24 Apr 2025
Truist Securities Richard Newitter 57% 1-year accuracy 29 / 51 met price target	1% downside $75	Hold Maintained	11 Apr 2025
Barclays Matt Miksic 48% 1-year accuracy 20 / 42 met price target	19% upside $90	Overweight Maintained	13 Feb 2025